Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

I watched. Thanks for posting the link. Quite informative. But I find myself getting more and more frustrated every time I hear about Breakthrough therapies that aren't bavituximab. I don't think any of us can argue that without the "data discrepancies" last fall, bavituximab would almost certainly have the designation already...if not some other accelerated designation such as fast-track or accelerated approval.

It just stinks to have to wonder how the FDA will now view an expedited pathway now that the trial has "issues". My fear is that all of the PD-1 drugs will be annointed and PPHM will be left to run the old standard phase III trial.